On Tuesday, AN2 Therapeutics Inc (NASDAQ: ANTX) was 9.26% up from the session before settling in for the closing price of $1.08. A 52-week range for ANTX has been $0.87 – $3.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 27.91%. With a float of $19.88 million, this company’s outstanding shares have now reached $30.14 million.
In an organization with 22 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
AN2 Therapeutics Inc (ANTX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward AN2 Therapeutics Inc stocks. The insider ownership of AN2 Therapeutics Inc is 34.12%, while institutional ownership is 36.69%. The most recent insider transaction that took place on May 28 ’25, was worth 218,000. In this transaction 10% Owner of this company sold 200,000 shares at a rate of $1.09, taking the stock ownership to the 3,017,432 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Chief Executive Officer bought 10,000 for $1.07, making the entire transaction worth $10,665. This insider now owns 256,380 shares in total.
AN2 Therapeutics Inc (ANTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.91% per share during the next fiscal year.
AN2 Therapeutics Inc (NASDAQ: ANTX) Trading Performance Indicators
You can see what AN2 Therapeutics Inc (ANTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.34 in one year’s time.
Technical Analysis of AN2 Therapeutics Inc (ANTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.82 million. That was better than the volume of 0.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 41.67%. Additionally, its Average True Range was 0.07.
During the past 100 days, AN2 Therapeutics Inc’s (ANTX) raw stochastic average was set at 31.48%, which indicates a significant decrease from 80.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.24% in the past 14 days, which was higher than the 54.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1953, while its 200-day Moving Average is $1.2081. However, in the short run, AN2 Therapeutics Inc’s stock first resistance to watch stands at $1.2200. Second resistance stands at $1.2600. The third major resistance level sits at $1.3300. If the price goes on to break the first support level at $1.1100, it is likely to go to the next support level at $1.0400. The third support level lies at $1.0000 if the price breaches the second support level.
AN2 Therapeutics Inc (NASDAQ: ANTX) Key Stats
There are 30,176K outstanding shares of the company, which has a market capitalization of 35.61 million. As of now, sales total 0 K while income totals -51,320 K. Its latest quarter income was 0 K while its last quarter net income were -10,650 K.
